C J van Asperen
Overview
Explore the profile of C J van Asperen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
42
Citations
846
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kramer C, Lanjouw L, Ruano D, Elst A, Santandrea G, Solleveld-Westerink N, et al.
J Pathol
. 2023 Oct;
262(2):137-146.
PMID: 37850614
The identification of causal BRCA1/2 pathogenic variants (PVs) in epithelial ovarian carcinoma (EOC) aids the selection of patients for genetic counselling and treatment decision-making. Current recommendations therefore stress sequencing of...
2.
Bakhuizen J, Hogervorst F, Velthuizen M, Ruijs M, van Engelen K, van Os T, et al.
Fam Cancer
. 2019 Jan;
18(2):273-280.
PMID: 30607672
Early-onset breast cancer may be due to Li-Fraumeni Syndrome (LFS). Current national and international guidelines recommend that TP53 genetic testing should be considered for women with breast cancer diagnosed before...
3.
Van der Hoeven N, Van Wijk K, Bonfrer S, Beltman J, Louwe L, de Kroon C, et al.
Clin Oncol (R Coll Radiol)
. 2018 Apr;
30(8):463-471.
PMID: 29691126
The optimal management of breast cancer susceptibility gene (BRCA)1/2 carriers with isolated serous tubal intraepithelial carcinoma (STIC) found at risk-reducing salpingo-oophorectomy (RRSO) is unclear. The prevalence of occult carcinoma and...
4.
Moghadasi S, Grundeken V, Janssen L, Dijkstra N, Rodriguez-Girondo M, van Zelst-Stams W, et al.
Clin Genet
. 2017 Jun;
93(1):52-59.
PMID: 28589637
Brcapro: 1.02, 95% CI: [0.75-1.38] and 0.94, 95% CI: [0.68-1.31], respectively). Myriad underestimated the number of carriers in up to 69% of the cases. BRCAPRO showed a non-significant, higher AUC...
5.
de Jonge M, Mooyaart A, Vreeswijk M, de Kroon C, van Wezel T, van Asperen C, et al.
Eur J Cancer
. 2017 Jan;
72:215-225.
PMID: 28049106
Background: Uterine serous carcinoma (USC) shows greater morphological, clinical and molecular similarities to high-grade ovarian tubal serous carcinoma than to other types of endometrial cancer. As high-grade ovarian tubal serous...
6.
van Driel C, Oosterwijk J, Meijers-Heijboer E, van Asperen C, Zeijlmans van Emmichoven I, de Vries J, et al.
Breast
. 2016 Sep;
30:66-72.
PMID: 27639031
Objectives: Women seeking counseling because of familial breast cancer occurrence face difficult decisions, such as whether and when to opt for risk-reducing mastectomy (RRM) in case of BRCA1/2 mutation. Only...
7.
Hollestelle A, van der Baan F, Berchuck A, Johnatty S, Aben K, Agnarsson B, et al.
Gynecol Oncol
. 2015 May;
141(2):386-401.
PMID: 25940428
Objective: Clinical genetic testing is commercially available for rs61764370, an inherited variant residing in a KRAS 3' UTR microRNA binding site, based on suggested associations with increased ovarian and breast...
8.
Heemskerk-Gerritsen B, Seynaeve C, van Asperen C, Ausems M, Collee J, van Doorn H, et al.
J Natl Cancer Inst
. 2015 Mar;
107(5).
PMID: 25788320
Background: Previous studies have reported a breast cancer (BC) risk reduction of approximately 50% after risk-reducing salpingo-oophorectomy (RRSO) in BRCA1/2 mutation carriers, but may have been subject to several types...
9.
Wevers M, Schmidt M, Engelhardt E, Verhoef S, Hooning M, Kriege M, et al.
Fam Cancer
. 2015 Feb;
14(3):355-63.
PMID: 25700605
It is expected that rapid genetic counseling and testing (RGCT) will lead to increasing numbers of breast cancer (BC) patients knowing their BRCA1/2 carrier status before primary surgery. Considering the...
10.
Hilbers F, Vreeswijk M, van Asperen C, Devilee P
Clin Genet
. 2013 Sep;
84(5):407-14.
PMID: 24025038
Women with a family history of breast cancer have an approximately twofold elevated risk of the disease. Even though an array of genes has been associated with breast cancer risk...